Info Kinetics, Korean univ sign MoU for medtech trial

Updated on 13 November 2012

Info Kinetics and Yeungnam University Hospital, South Korea, signed MoU for collaboration in medical device testing and clinical trials. The MoU will lead to the development of first fully-structured medical device clinical trials center in Koridor Utara

info-kinetics-korean-univ-sign-mou-for-medtech-trial

Info Kinetics and Yeungnam University Hospital, South Korea, sign memorandum of understanding

Singapore: Info Kinetics and Clinical Trial Center for Medical Devices of Yeungnam University Hospital, South Korea, signed a memorandum of understanding (MoU) to establish co-operation and collaboration in medical device testing and clinical trials, including in-vitro biocompatibility testing according to ISO 10993, toxicology studies, leaching studies and medical devices clinical trials according to ISO 14155.

This MoU provides a platform for technical collaboration for compliance with Organization for Economic Co-operation and Development (OECD)'s good laboratory practice (GLP). It will also provide opportunities for technical internship placement between the two institutes. In addition, both parties will collaborate as bidding partners in a global trial proposal. Furthermore, this collaboration will also lay the foundation for the first fully-structured medical device clinical trials center in the Northern Corridor Economic Region (Koridor Utara).

Professor Sang-Ho Anh, director, clinical trial center of medical devices, Yeungnam University Hospital, South Korea, said that, "Although South Korea has been an OECD member country since 1995, there are very few OECD GLP laboratories, especially for medical device testing. The best strength offered by Info Kinetics is their six years of OECD GLP accreditation status."

The companies with significant manufacturing facilities in Koridor Utara include Ambu, Bard, B Braun, Covidien, Symmetry Medical, St Jude Medical, Teleflex and a home-grown company Vigilenz.

Dato' Redza Rafiq, chief executive, Northern Corridor Implementation Authority (NCIA), said that, "The collaboration in clinical trial and in-vitro biocompatibility testing will be able to support various entry point projects (EPPs) for ‘Healthcare and Medical Devices' under ‘Healthcare National Key Economic Area' (NKEA) announced last year. The seven EPPs launched in 2011 are expected to bring in some $5.57 billion (RM 17.1 billion) in revenue and a gross national income of $3.71 billion (RM 11.4 billion), as well as creating 86,000 employment opportunities by the year 2020."

Previous 1

Leave a Reply

Post Comment

Special Features

Survey Box

Chinese Bird Flu H5N7

Have Chinese scientists done the right thing by fusing human and avian flu strains to create new killer viruses?

Send this article by email

X